ArticleFrontiers in neurology2025
Global, regional and national burden of neck pain in children and adolescents: GBD 2021 systematic analysis.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neck pain (NP) has emerged as a significant health concern among children and adolescents, with potential lifelong consequences. This study aimed to comprehensively assess the global, regional, and national burden of NP among this population using data from the 2021 study. Methods: Publicly available modeled data and methods from the Global Burden of Disease (GBD) study 2021 were used to systematically analyze and evaluate the global burden of NP among children and adolescents. Primary outcomes were NP related age-standardized prevalence, incidence, years lived with disability (YLDs), and average annual percentage change (AAPC). Results: Between 1990 and 2021, the global prevalence of NP among children and adolescents increased from 8.49 million to 10.32 million cases, though age-standardized rates remained relatively stable (AAPC 0.01%). The global incidence of NP among children and adolescents increased from 3.17 million cases in 1990 to 3.82 million in 2021, while the age-standardized incidence rate showed a minimal decrease (AAPC -0.02%). The burden of NP in terms of YLDs increased from 0.89 million in 1990 to 1.08 million in 2021, although the age-standardized YLD rate remained stable (AAPC 0%). A pronounced age gradient was observed, with rates in 2021 peaking in the 15-19 years group (1,012.03 per 100,000) compared to the 5-9 years group (97.44 per 100,000), though the youngest group showed the largest relative increases over time (AAPC 0.10%). Females consistently exhibited 33.1% higher prevalence than males. High sociodemographic index (SDI) regions demonstrated the highest prevalence rates, with Western Europe (984.25 per 100,000), High-income North America (827.69), and Central Europe (751.30) leading, though low SDI regions showed more rapid increases. At the national level, Italy, Norway, and Denmark had the highest rates, while Middle Eastern countries experienced the most rapid increases. Conclusion: Despite stable global age-standardized rates, the increasing absolute burden of NP among children and adolescents remains concerning. This study provides strong evidence that there are diverse changing patterns of NP burden across different sex, age, and SDI groups within children and adolescents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.